TargetBeta
HCN4
hyperpolarization activated cyclic nucleotide gated potassium channel 4 · Cyclic nucleotide gated channels
1 program in company-led studies act on HCN4, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Dronedaronerule | Sanofi | phase 4 | 180 running | CACNA1C, CACNA1D, CACNA1F, CACNA1S, KCNJ2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Atrial Fibrillation, 1 program
- Heart Failure, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.